We have updated our forecasts following the FY2016 results release on 4th April. Our revised and more prudent valuation approach assumes direct sales of MTX110 (paediatric brain cancer) and MTD201 (in carcinoid syndrome), and launch of both products in 2020e. We look forward to the expected start of clinical trials for both programmes later this year. We retain a Buy with a target price of 140p.
15 May 2017
N+1 Singer - Midatech Pharma - New take on valuation and direct sales strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Midatech Pharma - New take on valuation and direct sales strategy
- Published:
15 May 2017 -
Author:
Dr Jens Lindqvist -
Pages:
6
We have updated our forecasts following the FY2016 results release on 4th April. Our revised and more prudent valuation approach assumes direct sales of MTX110 (paediatric brain cancer) and MTD201 (in carcinoid syndrome), and launch of both products in 2020e. We look forward to the expected start of clinical trials for both programmes later this year. We retain a Buy with a target price of 140p.